Neutralizing Antibody Screening Using Viral Glycoprotein EV Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining virus-neutralizing antibodies are cumbersome, time-consuming, and require handling infectious viruses, specialized equipment, and skilled personnel, making them unsuitable for high-throughput screening and automation.
Innovation Solution
A method using non-infectious extracellular vesicles (EVs) with viral glycoproteins and a label to detect virus-neutralizing antibodies by measuring reduced uptake of EVs by target cells, eliminating the need for infectious agents and genetic material.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional CPE-based assays are used to detect virus-neutralizing antibodies, then measurement precision is achieved, but productivity is severely limited due to tedious manual operations and time-consuming processes requiring several days
Solution Approach 1:
The patent uses virus-like particles (VLPs) as copies of infectious viruses. These VLPs contain viral glycoproteins that mimic the structure and function of real viruses for neutralization assays, but lack genetic material and cannot replicate. This allows high-throughput automated detection while maintaining measurement precision, resolving the contradiction between accurate detection and productivity
Solution Approach 2:
The patent replaces manual mechanical operations (microscopy, plaque counting, CPE observation) with automated flow cytometry-based detection. The uptake of VLPs by target cells is measured automatically through fluorescent labeling and flow cytometry, eliminating tedious manual steps and enabling high-throughput processing while maintaining detection accuracy
2Reliability
If infectious viruses are used in neutralization assays, then reliability of neutralization measurement is achieved, but object-affected harmful factors increase due to biosafety requirements and specialized facility needs
Solution Approach 1:
The patent extracts the essential functional components of viruses (glycoproteins) while removing the harmful elements (genetic material, replication capability). The resulting virus-like particles retain the ability to bind antibodies and mediate neutralization assays but cannot infect cells or replicate, eliminating biosafety risks while maintaining measurement reliability
Solution Approach 2:
The patent converts the harmful property of infectious viruses into a beneficial feature by using only the surface glycoproteins for assay purposes. The glycoproteins' natural ability to bind neutralizing antibodies is preserved and utilized, while the infectious and replicative capabilities are eliminated, turning a hazardous material into a safe diagnostic tool
3Reliability
If specialized laboratories with certification are used for virus handling, then reliability of assay results is maintained, but device complexity and ease of operation worsen due to specialized equipment and trained personnel requirements
Solution Approach 1:
The patent uses certified virus-like particles that replicate the diagnostic functionality of infectious viruses without requiring biosafety level 2 or higher facilities. The VLPs can be handled in standard laboratories using常规 equipment, eliminating the need for specialized infrastructure while maintaining assay validity through standardized production and characterization protocols
4Measurement precision
If manual operations are used in virus neutralization assays, then measurement precision is maintained, but productivity decreases and ease of operation worsens due to inability to automate
Solution Approach 1:
The patent replaces manual microscopy and plaque counting with automated flow cytometry detection. The fluorescently labeled VLPs are detected automatically as they pass through the flow cytometer, enabling precise quantification of neutralizing antibodies through automated data collection and analysis, thereby improving both ease of operation and productivity while maintaining measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables rapid, high-throughput, and automated detection of virus-neutralizing antibodies without specialized facilities or permissions, providing valuable insights into immune responses and vaccine efficacy.
Implementation Method 1
the one or more viral glycoprotein(s) is/ are able to target a receptor of said cells and is/ are fusogenic
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The invention provides a method for determining whether or not virus-neutralizing antibodies are present in a sample obtained from a subject and a respective kit therefore. The present invention further relates to an in vitro method for screening compounds for their ability to neutralize a virus.